$50,000 of ABBOTT LABORATORIES lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to global health policy and funding; Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75). Issues related to global health policy and funding."
You can find more data on corporate lobbying on Quiver Quantitative.
ABT Congressional Stock Trading
Members of Congress have traded $ABT stock 11 times in the past 6 months. Of those trades, 4 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $ABT stock by members of Congress over the last 6 months:
- REPRESENTATIVE RICHARD MCCORMICK has traded it 2 times. They made 2 purchases worth up to $30,000 on 03/19, 11/05 and 0 sales.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 1 purchase worth up to $15,000 on 11/18 and 2 sales worth up to $30,000 on 02/10, 12/19.
- REPRESENTATIVE THOMAS H. KEAN, JR. purchased up to $15,000 on 01/29.
- REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.
- REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 12/08.
- REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
ABT Insider Trading Activity
ABT insiders have traded $ABT stock on the open market 10 times in the past 6 months. Of those trades, 3 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $ABT stock by insiders over the last 6 months:
- ROBERT B FORD (CHAIRMAN AND CEO) purchased 18,800 shares for an estimated $2,013,966
- DANIEL J STARKS has made 2 purchases buying 10,000 shares for an estimated $1,087,331 and 0 sales.
- ERIC SHROFF (Senior Vice President) has made 0 purchases and 2 sales selling 2,295 shares for an estimated $284,988.
- LOUIS H. MORRONE (EXECUTIVE VICE PRESIDENT) sold 1,144 shares for an estimated $132,223
- DANIEL GESUA SIVE SALVADORI (EVP AND GROUP PRESIDENT) sold 885 shares for an estimated $102,288
- MARY K MORELAND (EXECUTIVE VICE PRESIDENT) sold 613 shares for an estimated $70,850
- JOHN A. JR. MCCOY (VICE PRESIDENT AND CONTROLLER) sold 585 shares for an estimated $67,614
- ELIZABETH C. CUSHMAN (EVP, GC AND SECRETARY) sold 263 shares for an estimated $30,397
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ABT Hedge Fund Activity
We have seen 1,252 institutional investors add shares of ABT stock to their portfolio, and 1,602 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- J. STERN & CO. LLP added 39,005,451 shares (+12439.6%) to their portfolio in Q4 2025, for an estimated $4,886,992,955
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 30,767,022 shares (-73.6%) from their portfolio in Q4 2025, for an estimated $3,854,800,186
- JPMORGAN CHASE & CO removed 7,190,072 shares (-24.5%) from their portfolio in Q4 2025, for an estimated $900,844,120
- ALLIANCEBERNSTEIN L.P. added 6,926,031 shares (+125.3%) to their portfolio in Q4 2025, for an estimated $867,762,423
- BLACKROCK, INC. added 5,348,812 shares (+3.8%) to their portfolio in Q4 2025, for an estimated $670,152,655
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 4,993,343 shares (-28.1%) from their portfolio in Q4 2025, for an estimated $625,615,944
- POLEN CAPITAL MANAGEMENT LLC removed 3,458,374 shares (-46.6%) from their portfolio in Q4 2025, for an estimated $433,299,678
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ABT Analyst Ratings
Wall Street analysts have issued reports on $ABT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 02/02/2026
- BTIG issued a "Buy" rating on 01/23/2026
To track analyst ratings and price targets for ABT, check out Quiver Quantitative's $ABT forecast page.
ABT Price Targets
Multiple analysts have issued price targets for $ABT recently. We have seen 12 analysts offer price targets for $ABT in the last 6 months, with a median target of $120.5.
Here are some recent targets:
- Adam Maeder from Piper Sandler set a target price of $115.0 on 04/17/2026
- Suraj Kalia from Oppenheimer set a target price of $115.0 on 04/17/2026
- Vijay Kumar from Evercore ISI Group set a target price of $120.0 on 04/17/2026
- Bruce D. Jackson from Benchmark set a target price of $120.0 on 04/17/2026
- Shagun Singh from RBC Capital set a target price of $130.0 on 04/17/2026
- Rick Wise from Stifel set a target price of $120.0 on 04/17/2026
- Travis Steed from B of A Securities set a target price of $120.0 on 04/17/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
